{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:32:14Z","timestamp":1782930734461,"version":"3.54.5"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Utilization of hematopoietic cell transplantation (HCT) for hematologic cancers previously demonstrated race, ethnicity, and age-based disparities.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate utilization over time by race, ethnicity, and age to determine if disparities persist in light of recent significant increases in HCT volume.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This US population-based retrospective cohort study includes patients who received transplants from January 2009 to December 2018. Data collection and cleaning occurred from February 2019 to November 2021, and data analysis occurred from January 2022 to October 2023. Method 1 restricted the analysis to Surveillance, Epidemiology and End Results (SEER) reporting areas for cases and transplants. Method 2 applied SEER age-, race-, and ethnicity-specific incidence rates to corresponding US census population and included all transplants reported to the Center for International Blood and Marrow Transplant Research. Race and ethnicity groups were hierarchically defined as Hispanic (any race), non-Hispanic White, non-Hispanic Black, and non-Hispanic Other (Asian and American Indian).<\/jats:p><\/jats:sec>Exposure<\/jats:title>Receipt of HCT.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Utilization rate of autologous or allogeneic HCT for patients with hematologic cancers by age, race, and ethnicity.<\/jats:p><\/jats:sec>Results<\/jats:title>From 2009 to 2018, 136\u202f280 HCTs were analyzed for 6 hematologic cancers comprising 16.7% pediatric\/adolescent\/young adults (0-39 years), 83.3% adults (40-84 years), 58% male, 10.3% Hispanic, 11.4% non-Hispanic Black, 3.8% non-Hispanic Other, and 74.5% non-Hispanic White patients, with 49\u202f385 allogeneic and 86\u202f895 autologous HCTs performed. HCT utilization increased over time for all disease, age, race, and ethnic groups. From 2017 to 2018, adult (40-84 years) allogeneic transplant utilization for acute myeloid leukemia and myelodysplastic syndrome (MDS) was similar for Hispanic and non-Hispanic White or Other patients but was lower for non-Hispanic Black patients (acute myeloid leukemia: 19% vs 13%; MDS: 9%-10% vs 5%). Similarly, autologous transplant utilization for lymphoma was similar for all race and ethnicity groups; however, autologous transplant for multiple myeloma was highest for non-Hispanic White patients and lower for all other groups (31% vs 26%-27%). In patients aged 0 to 39 years, utilization of allogeneic transplant for acute lymphoblastic leukemia was highest in Hispanic patients, followed by non-Hispanic White, Black, and Other races (acute lymphoblastic leukemia: 19%, 18%, 17%, and 16%, respectively).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of autologous and allogeneic transplant utilization for hematologic cancers, disparities persisted for non-Hispanic Black patients. Hispanic, non-Hispanic Other, and younger age groups had increased utilization over time that was on par with non-Hispanic White patients in the most recent cohort.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.33145","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:01:43Z","timestamp":1726671703000},"page":"e2433145","source":"Crossref","is-referenced-by-count":14,"title":["Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age"],"prefix":"10.1001","volume":"7","author":[{"given":"Theresa","family":"Hahn","sequence":"first","affiliation":[{"name":"Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee"},{"name":"CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinalben","family":"Patel","sequence":"additional","affiliation":[{"name":"CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic-Florida, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Mayo Clinic-Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,18]]},"reference":[{"issue":"7","key":"zoi240998r1","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1200\/JCO.1997.15.7.2644","article-title":"Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors.","volume":"15","author":"Mitchell","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi240998r2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"zoi240998r3","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: effect of race and sex.","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"issue":"16","key":"zoi240998r4","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report.","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"19","key":"zoi240998r5","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi240998r6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jtct.2022.09.015","article-title":"Trends in allogeneic hematopoietic cell transplantation utilization and estimated unmet need among Medicare beneficiaries with acute myelogenous leukemia.","volume":"28","author":"Mau","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"zoi240998r7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"zoi240998r8","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1182\/bloodadvances.2023012469","article-title":"Trends in volumes and survival after hematopoietic cell transplantation in racial\/ethnic minorities.","volume":"8","author":"Khera","year":"2024","journal-title":"Blood Adv"},{"issue":"14","key":"zoi240998r12","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood.2021012830","article-title":"Structural racism is a mediator of disparities in acute myeloid leukemia outcomes.","volume":"139","author":"Abraham","year":"2022","journal-title":"Blood"},{"issue":"4","key":"zoi240998r13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/OP.23.00413","article-title":"Cost-effectiveness of reduced-intensity allogeneic hematopoietic cell transplantation for older patients with high-risk myelodysplastic syndrome: analysis of BMT CTN 1102.","volume":"20","author":"Saber","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"30","key":"zoi240998r14","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome.","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"30","key":"zoi240998r15","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","article-title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study).","volume":"39","author":"Kr\u00f6ger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi240998r16","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes.","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"zoi240998r17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes.","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"23","key":"zoi240998r18","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1002\/cncr.33826","article-title":"Blood and marrow transplant clinical trials network study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: challenges and opportunities in implementation.","volume":"127","author":"Warlick","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"zoi240998r19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1377\/hlthaff.2021.01394","article-title":"Systemic and structural racism: definitions, examples, health damages, and approaches to dismantling.","volume":"41","author":"Braveman","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"zoi240998r20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2337\/dci24-0019","article-title":"Living within the redlines: how structural racism and redlining shape diabetes disparities.","volume":"47","author":"Ogungbe","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"zoi240998r21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indication for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy.","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"zoi240998r9","unstructured":"Surveillance, Epidemiology and End Results Program. Accessed February 6, 2024. https:\/\/seer.cancer.gov"},{"key":"zoi240998r10","unstructured":"Registry Groupings in SEER Data and Statistics. Accessed February 6, 2024. https:\/\/seer.cancer.gov\/registries\/terms.html"},{"key":"zoi240998r11","unstructured":"SEER. Number of Persons by Race and Hispanic Ethnicity for SEER Participants. Accessed January 3, 2024. https:\/\/seer.cancer.gov\/registries\/data.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2823678\/hahn_2024_oi_240998_1725649656.63967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T15:01:45Z","timestamp":1726671705000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2823678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.33145","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}